RxDoctor Payments Data

Ted Huang, MD

Hematology & Oncology · Gresham, ORNPI 1356469902

Payments from drug & device makers

What this record shows

This record is dominated by education: $35 of the $35 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for hematology & oncology clinicians in OR, where the typical reported total is $847.

$35in general payments, 2019–2025

Across 2 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$35
$746,014in research payments, 2019–2025

Across 15 payments — averaging $49,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$606K
  • Pfizer$126K
  • Genentech, Inc.$14K

What the payments were for

  • Education$35100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$35

How this compares

$35 in reported general payments places this provider in the 5th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$53,508
Medicare patients
221
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate52$866,669
BrukinsaZanubrutinib19$291,279
MekinistTrametinib Dimethyl Sulfoxide18$264,685
TabrectaCapmatinib Hydrochloride11$244,896
TafinlarDabrafenib Mesylate18$243,786
InlytaAxitinib12$193,885
XtandiEnzalutamide14$182,062
EliquisApixaban33$30,320
Abiraterone Acetate54$12,728
Hydroxyurea119$2,367
Oxycodone Hcl60$1,581
Prochlorperazine Maleate35$736
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$357
Dexamethasone30$319
Prednisone60$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$35$224,20445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 112 hematology & oncology providers in Oregon.

Other hematology & oncology in Gresham

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →